glp 1 and ibd A schematic representation of the mechanism of glucagon-like peptide-1 GLP-1 based therapies and disease

Fatigue affects approximately 30% of patients in the first 8 weeks of GLP-1 therapy, though most experience improvement by week 12

Delaying gastric emptying: slowing digestion, which helps to reduce hunger

Notably, the current evidence base for GLP-1 RAs in MC4R -deficient obesity spans a wide age range, from children as young as 9 years to adults, yet pediatric-specific considerations remain inadequately addressed

However, we argue that lacking adjustment of these factors will not bias our results because these factors might act as mediators instead of confounding factors based on the available evidence that poor glucose control will lead to DR, whereas using GLP-1 RAs will help to control glucose control